TCRX News & Events

Reports Q4 revenue $2.6M, consensus $2.42M "The regulatory and operational progress we have made over the last several months related to our heme program is exciting. We expect the momentum to continue into the second quarter when we plan to share the initial data from patients enrolled into Cohort C in the ALLOHA study as well as initiate TScan's first Phase 3 trial," said Gavin MacBeath, CEO. "The data we presented at ASH in December 2025 continue to support our decision to focus the Company's efforts on development of therapeutics for patients with heme malignancies. Additionally, the recent FDA clearance of INDs for TSC-102-A01 and TSC-102-A03 will allow us to bring our TCR-T therapies to twice as many patients who currently have limited options in the post-transplant setting."

TScan Therapeutics announced completion of enrollment into Cohort C of the ALLOHA study. Patients in Cohort C are being treated using the new commercial-ready manufacturing process. The Company also announced that the U.S. Food and Drug Administration, FDA, has cleared its investigational new drug, IND, applications for TSC-102-A01 and TSC-102-A03 for patients with HLA types A 01:01 and A 03:01, respectively.